Zacks Analyst Blog Highlights: Cabela’s Inc., Sanmina-SCI Corp., Dollar Financial Corp., Inspire Pharmaceuticals, Inc. and Allergan, Inc.

CHICAGO--(BUSINESS WIRE)--Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Cabela’s Inc. (NYSE: CAB), Sanmina-SCI Corp. (Nasdaq: SANM), Dollar Financial Corp. (Nasdaq: DLLR), Inspire Pharmaceuticals, Inc. (Nasdaq: ISPH) and Allergan, Inc. (NYSE: AGN).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579

Here are highlights from Tuesday’s Analyst Blog:

Cabela's Seeking Catalysts

Cabela’s Inc. (NYSE: CAB) is a direct marketer and a retailer of hunting, fishing, camping and related outdoor merchandise. The company reported disappointing results for the third quarter. Its sales were $5 million below consensus and its EPS were $0.06 below consensus.

The difficult macro economic conditions continue to negatively affect consumer spending and Cabela’s’ results. Citing the weak environment, the company tempered its outlook.

Sanmina-SCI Dwindling Away

Sanmina-SCI Corporation (Nasdaq: SANM) is currently struggling with an industry-wide weakness and challenging end-market demand. After exiting its PC business, Sanmina has focused on its core business and margin improvement.

Although, Sanmina has reduced its cost structure, topline growth is sluggish and we believe the company will struggle to grow again in 2009 as well. However, we would like to see sustained growth before becoming more positive on the stock.

Dollar Fincl a Buy in Lean Times

Dollar Financial Corp. (Nasdaq: DLLR), located in Berwyn, Pennsylvania, is an international financial services company serving under-banked consumers. DLLR provides a range of consumer financial products and services primarily consisting of check cashing, short-term consumer loans, Western Union money orders and money transfers, along with other conveniences such as utility bill payments, currency exchange, and tax preparation.

DLLR's 1Q09 (ended September 30, 2008) diluted earnings of $0.55 per share were ahead of consensus estimates. The company continued to deliver outstanding revenue growth (17.0% during the reported quarter), despite difficult economic environment. Net income increased by 12.9%, based on strong growth especially in the U.S. markets, as a result of acquisitions. After reviewing the 1Q09 results, we are adjusting our FY09 and FY10 estimates.

Inspire Pharma Inspirational to $7

Inspire Pharmaceuticals, Inc. (Nasdaq: ISPH) is a specialty pharmaceutical company focused on the development and commercialization of treatments for respiratory and ophthalmologic disorders. Currently, the company has three products on the market and a robust pipeline.

We see strong top-line growth from 2008 and beyond. Inspire Pharmaceuticals just reported positive phase III data of Denufosol for CF [cystic fibrosis]. The company has a strong collaborative alliance with Allergan Pharmaceuticals (NYSE: AGN) for key products that treat dry eyes and allergic conjunctivitis.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=2649.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=2677

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4580.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.